Cardiac complications from multisystem inflammatory syndrome associated with prior COVID-19 infection

Krishna Patel,1 Rahul Mehta,2 Yaqub M Betz,3 Louise M Man3

SUMMARY
Multisystem inflammatory syndrome in adults (MIS-A) is a systemic inflammatory condition that presents roughly 4–6 weeks after initial COVID-19 infection. Patients typically present with persistent fevers, widespread rash, abdominal pain, vomiting and diarrhoea, and new-onset neurological symptoms. Cardiac dysfunction is a prominent feature of COVID-19 sequelae due to the abundance of ACE2 receptors on cardiac tissue. Delayed diagnosis due to the novelty of MIS-A can lead to cardiac complications like heart failure and shock, which could result in chronic cardiac disease. Avoidance of complications and chronic illness is possible with prompt corticosteroid therapy. Despite patient recovery to baseline level of function, surveillance of cardiac function to screen for chronic cardiac disease in the follow-up period is recommended. We present a case of MIS-A in a young man, compare his presentation with other similar cases and discuss implications of delayed diagnosis.

BACKGROUND
With the increasing prevalence of COVID-19 infections and the ongoing evolution of variants of the SARS-CoV-2 virus, multisystem inflammatory syndrome in adults (MIS-A) associated with prior COVID-19 infection is being identified in more patients worldwide. MIS-A is a hyperinflammatory syndrome that afflicts patients in the postinfectious period, typically 4–6 weeks after initial COVID-19 infection. Despite the rising number of MIS-A cases, diagnosis and treatment are often delayed due to multiorgan involvement and the absence of universal diagnostic criteria. Additionally, the novelty of this COVID-19 sequela and consequent lack of clinician awareness may result in extensive evaluation for alternative etiologies, such as rare infectious pathogens and malignancies, which can ultimately delay the initiation of treatment. During this time, patients with MIS-A may experience rapid clinical deterioration with potential development of complications arising from the rampant inflammation that may be avoidable with earlier diagnosis. We present a case of MIS-A complicated by cardiovascular illness in a young adult, and discuss how clinicians can avoid consequences of delayed diagnosis and treatment.

CASE PRESENTATION
A man in his late 30s, with only known medical history of anxiety and depression, was admitted to a local community hospital for acute hypoxic respiratory failure 1 week after testing positive for COVID-19 by PCR test. During his 9-day hospital course, the patient improved with high flow nasal cannula (NC) oxygen therapy, antibiotics and dexamethasone, and was discharged with a tapered prednisone course starting at 20 mg daily.

Four days later, he was readmitted there with recurring fever to 39.4°C and persistent generalised weakness. Blood tests during this admission were significant for a white cell count (WCC) of 33.2×109/L, neutrophilia (absolute neutrophil count 26.9×109/L), anaemia (haemoglobin 125 g/L) and lactic acidosis (lactate 3.4 mmol/L). Further admission laboratory assessment was notable for elevations in ferritin (74,564 ng/mL), C reactive protein (CRP) (20.3 mg/L), D-dimer (14.57 mg/L) and procalcitonin (14.3 ng/mL). COVID-19 PCR test on admission was negative. CT pulmonary angiogram was done due to elevated D-dimer, and showed multiple segmental pulmonary emboli and multifocal airspace opacities with medistinal and hilar adenopathy. A transthoracic echocardiogram (TTE) was obtained for workup of pleuritic chest pain which revealed a newly reduced left ventricular ejection fraction (LVEF) of 38% (video 1) using the biplane Simpson’s method. Despite the initiation of broad-spectrum antibiotics, the patient continued to have nightly fevers to 39°C. This led to an extensive workup for autoimmune and infectious processes that was ultimately negative (table 1).

A bone marrow biopsy was done and showed no findings of an underlying haematological malignancy. A second COVID-19 PCR test was negative. After 15 days there, he was transferred to our facility for further evaluation.

On presentation to our hospital, the patient reported persistent fevers despite improving leucocytosis and inflammatory markers (table 2, day 1). On evaluation, the patient was febrile to 38.5°C, tachycardic to 105 beats/min and tachypnoeic to 18 breaths/min but remained normotensive (121/64 mm Hg) with normal oxygen saturation on room air. Physical examination revealed normal heart sounds, clear lung fields to auscultation and generalised abdominal tenderness to deep palpation.

INVESTIGATIONS
The extensive workup which was initiated at the outside hospital was continued and also broadened after arrival to our facility. Early on during his admission, ECG showed sinus tachycardia and left ventricular hypertrophy (figure 1). Repeat TTE showed recovered systolic function with LVEF of 60%–65%.

The patient was evaluated for bacterial and viral infections but also fungal, tickborne and parasitic infections; all were ultimately negative (table 1).

To cite: Patel K, Mehta R, Betz YM, et al. BMJ Case Rep 2022;15:e249889. doi:10.1136/bcr-2022-249889
Autoimmune evaluation was also pursued and unremarkable (table 1).

Given his negative infectious workup, recent COVID-19 infection, high fever, anaemia and elevated ferritin levels, he was evaluated for possible haemophagocytic lymphohistiocytosis.

NK cell quantitation was normal, but soluble interleukin-2 receptor (sIL-2R) level was elevated to 2733.1 pg/mL (reference range 175.3–858.2 pg/mL). His prior bone marrow biopsy specimen was reviewed at our facility. It revealed normocellular marrow with trilineage haematopoiesis, with no significant dysplasia or increase in blasts. There were no findings of haemophagocytosis.

On hospital day 3, the patient was febrile to 39.6°C, tachycardic to 136 beats/min and required 2L of oxygen via NC concerning for sepsis with subsequent chest radiograph showing bibasilar lung opacities and bilateral pleural effusions (figure 2). Follow-up CT scan of the chest revealed symmetric, hazy ground glass opacities in the lungs and bilateral pleural effusions (figure 3). Thoracentesis was performed with fluid analysis revealing exudative effusion by Light’s criteria, which ultimately did not yield an infectious organism (table 3).

Bronchoscopy was attempted but aborted due to respiratory instability. During this time, his fevers persisted despite acetaminophen and ibuprofen.

On hospital day 5, the patient acutely developed pleuritic chest pain, significant tachycardia, hypotension, increased work of breathing, and need for supplemental oxygen. Urgent TTE demonstrated moderate to large pericardial effusion and late diastolic collapse of the right ventricle, concerning for cardiac tamponade (video 2, figure 4). The patient underwent emergent pericardiocentesis, with removal of 463 mL of serosanguinous fluid and placement of a pericardial drain. Postprocedure echocardiogram demonstrated minimal residual pericardial fluid. While WCC more than 25×10⁹/L were in the pericardial fluid, cultures were negative for both bacterial and fungal sources of infection, and pathology revealed significant inflammation (table 4).

The pericardial drain was removed 7 days after placement with follow-up echocardiograms demonstrating minimal pericardial fluid and no evidence of tamponade.

### Differential diagnosis

Due to the persistence of the patient’s high fever and an array of systemic inflammatory symptoms, infectious and rheumatological processes were all considered but eventually excluded. HLH was ruled out given normal bone marrow biopsy results, lack of cytopenias and normal NK cell activity. Myocarditis from potential severe COVID-19 reinfection was felt to be unlikely due to multiple negative PCR tests. In addition to this, the significantly elevated leucocyte count with a predominance of segmented neutrophils far above the upper limits of normal for pericardial fluid studies, in the context of sterile cultures pointed to a hyperinflammatory response that was confirmed by pathology. Therefore, with such broad workup being unremarkable but with persistent fevers in spite of broad-spectrum antibiotics, multiorgan involvement, and a COVID-19 infection that was, at this point about 5 weeks prior, MIS-A associated with prior COVID-19 infection became the working diagnosis.

### Treatment

After MIS-A became the presumed diagnosis, the patient began corticosteroid therapy on hospital day 6, 1 day after pericardiocentesis. He was treated with intravenous methylprednisolone 80 mg daily for 4 days. Additionally, he was treated for pericarditis with a 5-day course of colchicine and non-steroidal anti-inflammatory drugs. Within 24 hours of treatment initiation, the patient’s vitals stabilised. The patient remained afebrile for the remainder of his hospital course with marked improvement in pleuritic chest pain. Leucocytosis improved to a WCC of 12.98×10⁹/L on day of discharge. After 4 days of methylprednisolone, he was transitioned to...
Case report

prednisone, with plans to taper over 3 weeks. Repeat TTE on discharge revealed LVEF of 60%–65% and trivial pericardial effusion. The patient continued treatment of systolic heart failure with metoprolol and losartan throughout his hospitalisation and at discharge. He was ultimately discharged on hospital day 14.

OUTCOME AND FOLLOW-UP

One week after discharge, the patient continued to have dizziness and chest pain. He was still taking prednisone, metoprolol and losartan. Approximately 1 month later, at his follow-up with his primary care physician, he reported symptomatic improvement and only mild dizziness with exertion along with lower extremity oedema for which he was started on torsemide. At outpatient follow-up with cardiology, the patient was diagnosed with American Heart Association Stage C chronic systolic heart failure with recovered LVEF with New York Heart Association Class III symptoms. During this visit, his metoprolol dose was decreased and torsemide was discontinued in light of euvolaemia. He returned to work, but with limitations due to diminished exercise tolerance, and persistent exertional dyspnoea. The patient has ongoing follow-up with cardiology.

DISCUSSION

Rapid viral replication during COVID-19 infection causes massive endothelial cell death and vascular permeability that triggers an acute cytokine storm, resulting in a systemic inflammatory response and multiorgan damage. This systemic inflammation can cause a range of clinical manifestations with varying severities, which has led to the identification of multiple sequelae of COVID-19. Since the onset of the global pandemic, there are increasing number of reports of patients who experience persistent symptoms or organ dysfunction weeks after acute COVID-19 infection, characterised as post-COVID-19 syndrome (colloquially known as ‘long COVID-19’) or MIS. Since data on the wide constellation of illnesses are limited, continuous efforts are being made by organisations such as the Centers for Disease Control and Prevention (CDC) to create diagnostic criteria and management strategies for COVID-19 sequelae.

Since the identification of MIS in children (MIS-C) associated with COVID-19 infection in April 2020, the CDC has extended their definition to include adults over the age of 21, leading to the preliminary diagnostic criteria for MIS-A (box 1).

Despite this preliminary definition, diagnosis and treatment of MIS-A is often delayed due to its novelty and since further evaluation of patients requires time.

We reviewed five case reports of adult cases of MIS-A with evidence of cardiac dysfunction, a case series of 16 patients published by the CDC, and a recently published systematic review of 221 patients, which represents the largest cohort of reported MIS-A cases.

Based on the literature, symptom onset occurred 4–6 weeks after prior symptomatic illness from acute COVID-19 infection. Most patients present with high fever, hypotension, gastrointestinal distress, cardiac dysfunction and diffuse maculopapular rash. Despite the involvement of multiple systems, significant respiratory illness and hypoxia that characterises acute COVID-19 infection is typically not seen. Regarding laboratory testing, most patients present with elevated inflammatory markers (CRP, ferritin, procalcitonin) and elevated markers of coagulopathy (D-dimer). There is an increased occurrence of MIS-A among the following populations: younger age groups, males and minorities (Hispanic

| Laboratory test | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 | Day 11 | Day 12 | Day 13 | Day 14 |
|----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| White cell count (×10^9/L) | 16.4 | 16.8 | 20.0 | 17.0 | 22.7 | 27.5 | 16.0 | 17.3 | 16.7 | 15.5 | 17.1 | 30.3 | 15.9 | 13.0 |
| Neutrophil count (×10^9/L) | 13.7 | 16.1 | 18.4 | 14.6 | 13.6 | 22.3 | 14.9 | 13.6 | 11.5 | 11.5 | 15.0 | 28.6 |     |     |
| Platelets (×10^9/L) | 480 | 514 | 498 | 473 | 621 | 487 | 442 | 489 | 559 | 501 | 564 | 554 | 535 | 494 |
| Haemoglobin (g/L) | 94 | 98 | 90 | 87 | 93 | 84 | 83 | 80 | 90 | 90 | 99 | 106 | 101 | 103 |
| Ferritin (ng/mL) | 40 000 |     |     |     |     |     |     |     |     |     |     |     |     |     |
| C reactive protein (mg/L) | 17.1 |     |     |     |     |     |     |     |     |     |     |     |     |     |

Figure 1  ECG consistent with sinus tachycardia and left ventricular hypertrophy. aVR, Augmented Vector Right; aVL, Augmented Vector Left; aVF, Augmented Vector Foot.

Figure 2  Chest X-ray showing bibasilar opacities and bilateral pleural effusions.
and non-Hispanic black patients). It is difficult to distinguish whether these populations have an increased inherent risk of developing MIS-A or if their increased risk is based on the health inequalities that minority communities face. Our patient meets all three of these population demographics.

In the systematic review of 221 MIS-A cases, only 32% of 192 patients tested positive on PCR and serological tests during hospitalisation for MIS-A. However, 98% of 211 patients had evidence of current or past COVID-19 infection via PCR and serological testing. Given the wide array of symptoms and non-specific findings in MIS-A, it is important to evaluate for recent COVID-19 infection and exposure on initial patient presentation. By assessing history of recent viral illness and obtaining laboratory evidence of current or past COVID-19 infection, diagnosis of MIS-A can be made in a timely fashion and treatment can be commenced. Delayed onset of treatment can lead to prolonged hospital stays and severe complications, as seen in our patient.

Most COVID-19 patients have evidence of cardiac dysfunction indicated by elevated troponin levels or abnormal echocardiographic findings. The high incidence of cardiac dysfunction in COVID-19 patients is thought to stem in part due to the abundant expression of ACE2 receptors on the myocardium that rivals the lungs. ACE2 is a surface enzyme expressed on multiple organs, but most notably the heart, and has been shown to play a role in hypertension, heart failure and myocardial infarction. With regard to COVID-19, it has been shown that the virus will enter cardiomyocytes via interaction between the SARS-CoV-2 spike protein and the N-terminal segment of the ACE2 receptor. Following entry of the virus into the cardiomyocyte, there is inhibition of metabolic pathways which induces a cytotoxic response in cardiomyocytes leading to significant inflammation and fibrosis which ultimately result in cardiac injury and dysfunction.

Prior COVID-19 infection can trigger a systemic proinflammatory state and a dysregulated immune response, leading to development of MIS-A. Factors such as preexisting comorbidities and inflammation due to ageing in adults can obscure and complicate MIS-A compared with children. In the systematic review of 221 MIS-A cases, a great proportion of patients with MIS-A presented with myocarditis and cardiac dysfunction compared with 3639 paediatric patients with MIS-C (p<0.001).

In a case series of 33 paediatric patients with MIS-C, 73% of patients had abnormal cardiac testing (evident by ECG, echocardiogram and serum cardiac biomarkers). All patients in the MIS-C case series with evidence of cardiac dysfunction had normal cardiac testing on discharge. Given the prolonged inflammatory state present in MIS-A and evidence of cardiac dysfunction as a common finding in COVID-19 sequelae, patients diagnosed with MIS-A should undergo cardiac testing and imaging with ECG and echocardiogram on presentation and prior to discharge. In addition, throughout a patient’s treatment course, there should also be low threshold for evaluation of disorders of the pericardium, and specifically the development of tamponade physiology, as without urgent intervention, patients can quickly progress to shock and death.

Table 3 Pleural fluid studies

| Laboratory test     | Results          |
|---------------------|------------------|
| pH                  | 7.3              |
| Glucose             | 114 mg/dL        |
| Protein             | 4.4 g/dL         |
| Lactate dehydrogenase | 741 U/L       |
| White cell count    | 0.920×10^9 cells/L |
| Segment neutrophils | 83%              |
| Lymphocytes         | 10%              |
| Monocyte/macrophage | 7%               |
| Culture             | No growth        |
| Gram stain          | 1+ white blood cells, no bacteria seen |

Figure 3 CT of the chest showing bilateral hazy ground glass opacities (arrow) and bilateral pleural effusions.

Figure 4 CT pulmonary angiogram demonstrating moderate-to-large pericardial effusion (arrow).

Video 2 Transthoracic echocardiography demonstrating moderate-to-large pericardial effusion with late diastolic collapse of right ventricle, causing concern for cardiac tamponade.
MIS-A can be treated with corticosteroid therapy, intravenous Ig, or immune modulators like tocilizumab. All patients in the individual case reports had marked symptom improvement with some variation of treatments previously described.

On review of the patient’s clinical course, we believe the patient’s initial presentation of MIS-A was likely on the day of readmission to the outside hospital, which was roughly 3 weeks after his initial positive COVID-19 PCR test. If this is the case, the patient ultimately started corticosteroid therapy 21 days after his initial presentation of MIS-A. During this delay in diagnosis and treatment, the patient developed acute systolic heart failure and obstructive shock secondary to acute pericardial tamponade. On reflection, both cardiac injuries might have been avoided with earlier initiation of corticosteroid therapy. Despite normalisation of our patient’s cardiac function on discharge, avoidance of earlier initiation of corticosteroid therapy is recommended.

Sequela of COVID-19 remain a novelty to the medical community. Better defined classifications and diagnostic criteria are needed to prompt the timely diagnosis and management of MIS-A. Furthermore, greater efforts are required to understand the long-term effects of COVID-19 infection on physiology and its impact on development of chronic diseases after resolution of viral infection.
Case report

2 Parums DV. Editorial: multisystem inflammatory syndrome in adults (MIS-A) and the spectrum of COVID-19. Med Sci Monit 2021;27:e935005.
3 CDC. Multisystem inflammatory syndrome (mis), centers for disease control and prevention, 2020. Available: https://www.cdc.gov/mis-a/hcp.html [Accessed 4 Jan 2022].
4 Mittal N, Abhelewa M, Brogan J, et al. A case report of multi-system inflammatory syndrome in adults (MIS-A) associated with heart failure. Eur Heart J Case Rep 2021;5:ytab381.
5 Vujaklija Brajković A, Zlopaša O, Gubarev Vrdoljak N, et al. Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19. Clin Res Hepatol Gastroenterol 2021;45:101678.
6 Gurin MI, Lin YJ, Bernard S, et al. Cardiogenic shock complicating multisystem inflammatory syndrome following COVID-19 infection: a case report. BMC Cardiovasc Disord 2021;21:522.
7 Shen M, Milner A, Foppiano Palacios C, et al. Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report. Eur Heart J Case Rep 2021;5:ytab470.
8 Kaufmann CC, Simon A, Reinhart-Mitocki D. Multisystem inflammatory syndrome in adults in a young male following SARS-CoV-2 infection—a case report. European Heart Journal - Case Reports 2021:ytab521.
9 Morris SB, Schwartz NG, Patel P, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020;69:1450–6.
10 Patel P, DeCuir J, Abrams J, et al. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review. JAMA Netw Open 2021;4:e2126456.
11 Mitrani RD, Diabas N, Goldberger JJ. COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020;17:1984–90.
12 Wick Z, Syleten C, Jakubik B, et al. A ce2 interaction networks in COVID-19: a physiological framework for prediction of outcome in patients with cardiovascular risk factors. J Clin Med 2020;9:3743.
13 Minocha PK, Phoon CKL, Verma S, et al. Cardiac findings in pediatric patients with multisystem inflammatory syndrome in children associated with COVID-19. Clin Pediatr 2021;60:119–26.

Copyright 2022 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.
Visit casereports.bmj.com for more articles like this and to become a Fellow